Dr. Matthew A. Gubens, mesothelioma expert and researcher

Matthew A. Gubens

Assistant Professor of Medicine, University of California San Francisco

Dr. Matthew Gubens is a thoracic oncologist who specializes in the treatment of lung cancer and pleural mesothelioma at the University of California San Francisco Comprehensive Cancer Center.

Get in touch

About Matthew A. Gubens

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • Immunotherapy icon


  • Board Certified icon

    Board Certified in Internal Medicine

Gubens is an assistant professor of medicine at the University of California San Francisco (UCSF), where his research focuses on the development of new therapeutic combinations to better help his patients.

He has clinical expertise in bronchioloalveolar carcinoma, chest-wall tumors, thymic carcinoma, mediastinal tumors, small cell and non-small cell lung cancer, and mesothelioma.

At UCSF, he works with both the thoracic oncology and hematology programs.

Gubens joined the UCSF Cancer Center in 2011 following his fellowship at the Stanford School of Medicine, where he also earned his medical degree.

He completed a residency in internal medicine at UCSF. He received a Master of Science degree from the Harvard School of Public Health and a bachelor’s degree from Yale University.

His research today includes designing clinical trials that study new drugs and treatment strategies. He has a special interest in translational medicine, which helps move lab-based findings into the clinic to benefit patients.

Importance of Immunotherapy

Gubens has played a role in several studies that have led to the increased use of Keytruda, an immunotherapy drug now being used by a growing number of lung cancer patients.

Although Keytruda has not been FDA approved yet for mesothelioma, it has been effective for a small percentage of mesothelioma patients in clinical trials and special-use exceptions.

Gubens often talks about his goal of developing more personalized treatments that can consistently help a larger percentage of patients.

In 2019, he co-authored several articles dealing with new immunotherapy treatment strategies for lung cancer that are now being tested for mesothelioma.

“It’s exciting to see the benefits of immunotherapy, and developing combinations that are effective in helping more patients,” Gubens said. “It’s an exciting area of research today.”

Disclaimer: Dr. Matthew A. Gubens has no professional affiliation with Asbestos.com.

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

Get the Best Treatment Options

Find a Doctor
Asbestos.com Mesothelioma Packet

Order Your Free Treatment Guide

Get Yours Now

Find a Mesothelioma Clinical Trial Near You

Get Help Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Daniel King, Content Writer for Asbestos.com
Edited by

3 Cited Article Sources

  1. University of California San Francisco Thoracic Oncology Program. (n.d.). Matthew A. Gubens, MD. : ,-md,-ms.aspx
    Retrieved from: https://top.ucsf.edu/meet-the-team/medical-oncologists/matthew-a-gubens
  2. Kratz, J. et al. (2019, July 14). Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging. Retrieve from:
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/30959120
  3. Gubens, M. & Davies, M. (2019, May 1). NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer. : Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/31117034

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

On This Page

Back to Top

Share this article

Last Modified August 28, 2019

Get Your Free Mesothelioma Guide Chat live with a patient advocate now